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Summary.-The production of carcinoembryonic antigen (CEA) by human breast
cancer tissue has been studied in relation to the prognosis of patients with breast
cancer. All of the patients were in a controlled trial of adjuvant chemotherapyfor the
treatment of operable breast cancer. CEA was studied in primary tumours and
axillary node metastases from these patients using an immunoperoxidase (PAP)
method. Sections of 290 primary carcinomas and 217 axillary metastases were
examined for CEA. The CEA status of the primary tumours was of no value as a
prognostic indicator nor in the selection of patients for chemotherapy. In contrast,
patients could be divided into 3 groups on the basis of the CEA results in the axillary
nodes. In one group, in which cases were strongly positive for CEA(24% of the total)
the prognosis, as reflected by recurrence free survival, was relatively good and
chemotherapy produced no further advantage. In another group in which cases were
weakly positive for CEA(18% ofthe total) the prognosis was poor but chemotherapy
produced significant improvement. In a third group, in which cases were negative
for CEA (58% of the total) the prognosis was poor and was not improved by chemo-
therapy, at least in the short term. Thus, the CEA status of axillary metastases
may be clinically useful.
THE PRODUCTION of carcinoembryonic
antigen (CEA) by human breast tumours
has been studied extensively. Several
reports have shown that serial measure-
ments of CEA in the serum can help to
monitor the clinical course ofpatients with
breast cancer (Steward et al., 1974;
Tormey et al., 1977; Falkson et al., 1978,
1979; Lamerz et al., 1980; Staab et al.,
1980a). However, serum measurements
may be influenced by certain variables
including the rate of production by
tumour cells and factors influencing release
of CEA into the circulation and excretion
by the liver (Bivins et al., 1975; Zamcheck
et al., 1975; Ellison et al., 1977; O'Brien et
al., 1980). An alternative method of CEA
detection, which is not subject to these
variables, is by immunohistochemistry
which permits precise localization of CEA
within individual tumour cells. Although
the disease cannot be monitored by this
method, attempts have been made to
correlate immunohistochemically demon-
strable CEA with various prognostic
parameters (Shousha & Lyssiotis, 1978;
Shousha et al., 1979; Walker, 1980).
However, conflicting results have been
obtained, probably attributable to differ-
ences in the characteristics of the CEA
antiserum used in the immunohisto-
chemical method (Walker, 1980).
In the present study the CEA status of
both primary and metastatic breast can-
cer, as demonstrated by an immunohisto-
chemical (immunoperoxidase) technique,
was correlated with the clinical course of
patients entered into a controlled trial of
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adjuvant chemotherapy for the treatment
of operable breast cancer. The aim was to
assess the value of CEA expression as a
prognostic indicator and as a means of
predicting which patients might benefit
from adjuvant chemotherapy.
MATERIALS AND METHODS
Patients.-All patients included in the
present study had been entered into a
multicentre randomized controlled trial of
adjuvant chemotherapy for operable breast
cancer which was initiated by the West
Midlands Oncology Association in 1977. The
protocol for this trial has been described
elsewhere (Morrison et al., 1981). Simple
mastectomy was performed and axillary node
status determined by axillary node sampling.
The present study is concerned exclusively
with axillary node positive patients. These
patients were allocated at random to either
surgery only ("control") or surgery plus
chemotherapy ("treated") groups. The
chemotherapy consisted of cyclophospham-
ide, methotrexate, 5 fluoro-uracil, vincristine
and adriamycin (Table I). This regimen of
TABLE I. Treatment schedule for node
positive patients
Time (h)
0
Drugs
Vincristino
Adriamycin
6 Cyclophosphamide
Methotrexate infusion
18 5-Fluoro-uracil
Leucovorin
15 mg orally 6 hourly x 3
1 mg i.v.
50 mg i.v.
250 mg i.v.
150 mg i.v.
(12 h)
250 mg i.v.
15 mg i.v.
chemotherapy was given at 3-weekly inter-
vals for a total of 6 months after surgerv. All
patients have been followed carefully in the
out-patient clinic and documented with
respect to recurrence free survival and overall
survival.
Immunoperoxidase technique.-The patho-
logical material used in the present study
consisted ofconventional formalin-fixed, wax-
embedded histological sections of primary
tumours and axillary node secondary deposits
removed at mastectomy. Representative sec-
tions ofthe primary tumour and of a variable
number (usually 1-3) of involved nodes from
each patient were sent from the pathology
departments of the contributing centres.
These were then examined for CEA using a
conventional three stage (PAP) immunoper-
oxidase technique, similar to that described
by Walker (1980). The primary anti-serum
was rabbit anti-carcinoembryonic antigen
(anti-CEA) serum (Dakoimmunoglobulins
A 115). Because this anti-serum contains
antibody directed against non-specific cross-
reacting antigen (NCA) it was absorbed,
before application, with a perchloric acid-
treated spleen extract, a source ofNCA. Neat
anti-CEA serum, spleen extract solution
(25 mg/ml) and TRIS buffer were mixed in a
volume ratio of 1:15:54, producing a final
dilution of anti-CEA serum of 1/70. After
incubation at 37°C for 4 h and centrifugation,
the supernatant was applied to the sections.
The specificity of the technique was
confirmed by several controls. When normal
rabbit serum and a hyperimmune anti-serum
(anti-ACTH) were substituted for anti-CEA
serum, negative results were obtained. The
anti-CEA serum was considered to be NCA-
free because of the absence of staining when
applied to sections of spleen and smears of
chronic myeloid leukaemia cells, tissue known
to contain NCA. Also red cells, which were
often present in sections of tumour, were
never stained suggesting that antibodies to
blood group antigens were absent from the
anti-CEA serum. When applied to sections of
a known CEA-secreting colonic carcinoma,
positive results were always produced, where-
as negative results were obtained with normal
tissue including breast, thyroid, pituitarv,
adrenal, lung and trachea. Anti-CEA serum
that had been absorbed with CEA antigen
(500 jug of CEA antigen was used to absorb
0-5 ml of a 1/70 dilution of CEA anti-serum)
gave consistently negative results when
applied to sections of colonic carcinoma and
previously positive primary breast tumours
and lymph node secondaries. (The CEA
antigen was kindly donated by Dr C. Ford
and Mr J. Griffin, Surgical Immunology Unit,
Clinical Oncology, Queen Elizabeth Hospital,
Birmingham.)
Assessment of sections. Sections stained
for CEA were assessed for the number of cells
showing a positive reaction; the intensity of
staining was not assessed. Results were
classified into 3 groups: one in which all cells
were negative for CEA (- group): one in
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which only a small number were positive (+
group) and one in which a large number were
positive (+ + group). In order to define the
point ofdivision between weakly positive (+)
and strongly positive (+ +-) cases in terms of
the percentage of tumour cells positive for
CEA and to assess how well the two groups
were separated, a sample ofthe positive cases
was formally quantitated by a cell count. The
same sample was used to determine whether
there was variation in CEA expression from
one area to another within primary tumours
and from one axillary metastasis to another
within individual patients. Thus sections from
2 or 3 different areas within each of 14
primary tumours and one section from
between 2 and 7 different axillary node
metastases from each of 34 individual
patients were assessed. All sections assessed as
weakly positive (+) contained <5% CEA
positive tumour cells whereas all sections
considered to be strongly positive (+ +)
contained >500 positive cells. Comparison of
results of CEA expression between different
areas of primary tumours and between
different axillarv metastases from individual
patients showed that in both situations there
was variation in results in 18% of cases when
the three categories -, + and + + were
used. Most ofthis, however, was due to the co-
existence of negative and weakly positive
areas both within primary tumours and
between axillary metastases. For this reason,
in order to reduce the influence of inter-site
variation of CEA expression to a minimum,
the major comparison made in this study is
based upon two groups, one in which negative
(-) and weakly positive (+) cases are
combined together and another which com-
prises only strongly positive (+ +) cases. In
this way, cases in which sections contained
<5% CEA positive tumour cells (including
all negative cases) were compared with those
in which sections contained > 5o positive
cells.
Sections of primary breast tumours from
290 patients (142 control and 148 treated) and
axillary node secondaries from 217 patients
(99 control and 118 treated) were examined
for CEA and categorized into -, + or + +
groups without prior reference to the clinical
course of the patients.
Other parameters.-In addition to immuno-
peroxidase staining for CEA, conventionally
stained sections of the primary tumours were
assessed for histological grade (Bloom &
Richardson, 1957). Also samples of primary
tumour cytosols were analysed for oestrogen
receptor content using the dextran-coated
charcoal method.
Statistical methods.-Correlations between
the CEA status and clinical course ofpatients
were performed using life table analysis. The
differences in disease free and actual survival
between the various groups under study were
demonstrated by using the Peto log-rank
method (Peto et al., 1977). For each compar-
ison life tables were constructed and a log-
rank x2 statistic estimated. All other
comparisons were performed using the con-
ventional x2 test. A P-value of <0.05 was
taken to be statistically significant.
RESULTS
CEA staining in primary and metastatic
breast cancer
Primary breast tumours from a total of
290 patients and axillary node secondaries
from a total 217 patients were studied for
CEA. Both primary and metastatic tum-
ours were examined in 209 patients, the
primary only in 81 patients and the
axillary metastasis only in 8 patients.
About one third of the primary tumours
were strongly positive (+ +) for CEA
whereas approximately one quarter of the
metastic tumours were in this group
(Table II). There was concordance be-
tween CEA results in primary and second-
ary tissue in 71% ofcases.
There was no significant correlation
between CEA status of either primary or
secondary tissue and (i) menopausal
TABLE II.-CEA results in primary and metastatic breast cancer
Primary tumours
Metastatic tumours
( )=o°/
CEA CEA
negative (-) )ositive (+)
111 (38) 80 (28)
124 (58) 40 (18)
CEA
negative (-) or
N eakly positive (+)
191 (66)
164 (76)
Strongly
CEA
positive (+ +)
99 (34)
53 (24)
290
217
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status, (ii) size ofthe primary tumour, (iii)
histological grade of the primary tumour
or (iv) oestrogen receptor status of the
primary tumour.
There was no difference morphologically
between CEA positive and negative tum-
our cells in either primary or metastatic
tissue.
Correlation of CEA status with clinical
course ofpatients
(Abbreviations used: N=number in
group; R =number of recurrences in
group; D=number of deaths in group;
- =negative for CEA; + =weakly posi-
tive for CEA; -/+ =combination of
negative andweaklypositive cases; + + =
strongly positive for CEA.)
The median duration offollow-up ofthe
patients inthis study was 2 years 7 months
(range 9 months to 4 years 7 months). At
this stage there was no significant differ-
ence in recurrence free survival between
the control (surgery only) and the treated
(surgery + chemotherapy) groups.
A. Primary tumours.-Recurrence-free
survival ofthe control group ofpatients in
which the primary tumours were negative
or weakly positive for CEA (- / +) was
compared with that of control patients in
which the primary tumours were strongly
positive for CEA (+ +). There was no
significant difference between the two
groups (-/+ group, N =92, R = 36; + +
group, N=50, R=19; P=0.80). The
group of patients that had received
adjuvant chemotherapy was examined in
the same way. There was again no
significant difference between the two
groups (-/+ group, N= 100, R= 38; + +
group, N=48, R=15; P=0.51). The
treatment and control subgroups of each
category of CEA results (i.e. -/+, + + )
were compared for recurrence-free sur-
vival. No significant differences were
present in either case (-/+ group
P= 0 39; + + group P= 0 34).
B. Axillary node metastases.-The same
methods of analysis were applied to CEA
results in axillary node metastases. Within
the control group of patients recurrence-
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FIG. 1.-Recurrence-free survival based on
CEA results in axillary metastases. Control
group only: comparison of -+ and + +
subgroups.
N R
-- - -1+ 78 38
+ + 21 4 P=0-036.
free survival was significantly better for
the CEA + + group than the CEA -/+
group (Fig. 1; + + group, N=21, R=4;
-/+ group, N=78, R=38; P=0-036).
When the same data were analysed using
actual survival there was a similar trend in
favour of the group strongly positive for
CEA but the difference was not significant
(++ group, N=21, D=1; -/+ group,
N=78, D=12; P=0.23). When the
chemotherapy group of patients was
analysed for recurrence free survival, no
significant difference was evident (+ +
C-)
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FIG. 2. Recurrence free survival based on
CEA results in axillary metastases. -l+
group only: comparison of control and
treated subgroups.
N R
Control 78 38
- - -Treated 86 31 P-=0-036.
L
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group, N= 32, R = 13; + group, N= 86,
R=31 ;P= 0.54).
CEA + + and CEA -/+ groups were
then analysed separately according to
treatment group. The results of com-
parison of recurrence-free survival of the
treated and control subgroups of patients
in the CEA -/ + category are shown in
Fig. 2. CEA -/ + patients in the treat-
ment group fare significantly better than
similar patients in the control group
(treatment group, N= 86, R= 31; control
group, N= 78, R= 38; P= 0.036). A sim-
ilar trend was seen for actual survival but
the difference was not significant (treat-
ment group, N = 86, D = 6; control group,
N=78, D=12; P=0.09). When the
treated and control subgroups of patients
in the CEA + + category were compared,
there was no statistically significant differ-
ence in recurrence free survival (treatment
group, N= 32, R= 13; control group,
N=21, R=4;P=0417).
..In view of the significant difference in
recurrence-free survival between the treat-
ment and control subgroups of the CEA
catego
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ment group, N = 65, R= 28; control group,
N= 60, R= 28: P= 0 37). However, when
patients with metastases weakly positive
for CEA were analysed independently
according to treatment group, it was found
that, despite small numbers, the recur-
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FiG. 4. Actual survival based on CEA results
in axillary metastases. +group only: com-
parison of control and treatedi subgroups.
N D
Control 18 5
- - - Treated 21 0 P=0O009.
category, the two components ofthis rence-free survival was very significantly
ry, i.e. - and +, were examined higher in the treatment group than the
btely. Comparison of treatment and control group (Fig. 3; treatment group,
)1 groups that were negative for CEA N= 21, R= 3; control group, N= 18,
d no significant difference (treat- R = 10; P = 0.005). When the same data
were analysed using actual survival there
was again a significant difference (Fig. 4;
treatment group, N=21, D=0; control
group, N= 18. D=5;P=0*009).
In order to exclude the possibility of
bias due to unequal distribution of known
prognostic factors, groups showing signi-
ficant differences were examined for the
following: menopausal status, size of
primary tumour, histological grade and
oestrogen receptor status. These factors
3. 5 730 1460 1825 were found to be evenly distributed
0 365 730 1095 1460 1825 between the groups under comparison.
TIME (DAYS) Finally, the proportion of recurrences in
3.-Recurrence free survival based on each group that occurred atlocoregional or
A results inaxillarymetastases. +group distant sites was compared. In everygroup y: comparison of control and treated between 60 and 7500 of the recurrences )groups. were locoregional, between 25 and 36%
Control 18 10 were distant and in 0-10% both sites were
--- Treated 21 3 P=0-005. involved.
v li
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DISCUSSION
The potential benefit of adjuvant
chemotherapy has to be set against the
cost of acute toxicity (Palmer et al., 1980),
the possibility of long-term organ damage
and induction of second tumours (Reimer
et al., 1977; Lerner, 1978; Valagussa et al.,
1980) and economic factors. On the basis
of present evidence it seems unlikely that
adjuvant chemotherapy will be of equal
benefit to all patients presenting with
breast cancer. It is clear, therefore, that
such treatment is only justifiable if it
substantially improves prognosis and that
there is a need for accurate discrimination
between those patients who will and those
who will not benefit from chemotherapy. A
number of important prognostic factors
have been defined for operable breast
cancer but their value as predictors of
response to chemotherapy remains to be
elucidated. The therapeutic value of the
chemotherapy regimen used in the West
Midlands Oncology Association Trial of
Adjuvant Chemotherapy for Operable
Breast Cancer will only become clear when
further follow-up allows analysis of the 5-
and 10-year survival figures. However,
interim analyses may reveal certain para-
meters which might be of potential value
in the selection of patients for
chemotherapy.
This study was designed to determine
whether the production of CEA by prim-
ary tumours and their nodal metastases
could be used in this way. From the results
presented, it is evident that the presence of
CEA in primary tumours is of no detect-
able prognostic value. However, the CEA
status ofthe axillary metastases does seem
to have some bearing upon the clinical
course of patients. Those in the control
group were shown to have a significantly
better chance of remaining free of recur-
rence if their nodal metastases were
strongly positive for CEA (> 50 positive
tumour cells), than if they were in the
combined negative and weakly positive
group (i.e. <5%o positive cells). In addi-
tion, no further advantage in recurrence-
free survival was produced by adjuvant
chemotherapy in the group with nodal
metastases strongly positive for CEA. It
would be interesting to extend the analysis
by subdividing the strongly positive cate-
gory using for example 25% CEA positive
cells as the cut-off point. At present how-
ever there is aninsufficient numberofpati-
ents in this category to permit satisfactory
statistical analysis of such subgroups.
In contrast, chemotherapy did result in
significantly better recurrence free sur-
vival when given to patients whose nodal
secondaries contained < 50 CEA-positive
cells (i.e. the - / + group) compared with
the control group. Also when those
patients with weakly positive results were
examined in isolation, adjuvant chemo-
therapy was shown to produce a highly
significant improvement in both recur-
rence-free survival and actual survival in
comparison with the control group. How-
ever, no significant improvement in the
prognosis of patients with CEA-negative
nodal metastases was seen during this
period offollow-up. From an assessment of
inter-site variation in CEA expression
(described under "assessment ofsections")
it is apparent that the negative and
weakly positive groups are not entirely
homogeneous. In some cases classed as
having negative axillary metastases, more
extensive sampling of nodes may have
revealed other metastases that were
weakly positive for CEA. Nevertheless
these 2 categories of CEA results (- and
+) in the axillary metastases, based on
limited sampling (1-3 involved nodes), do
seem to define groups of patients that
behave differently in terms of their
response to chemotherapy.
None of the significant differences dis-
cussed above could be explained by
unequal representation of certain good
prognostic features within the groups
compared, including small size of primary
tumour, good histological grade and the
presence of oestrogen receptor in the
primary tumour. Furthermore, since it has
been shown that survival after local
recurrence is longer than survival after
distant metastasis (Karabali-Dalamaga et
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al., 1978), the proportion of recurrences at
each ofthese sites was determined in each
of the groups. It was found, that in every
group approximately two-thirds of recur-
rences were locoregional and one-third
occurred at distant sites. Therefore, there
is no reason to suspect that differences in
mean duration of survival were produced
by mal-distribution of any of these
prognostic factors.
A possible explanation for the observed
relationship between axillary node CEA
status and prognosis and response to
chemotherapy is suggested by data from
in vitro studies (Drewinko & Yang, 1976,
1980; Ellison et al., 1977; Rutzky et al.,
1979). It has been shown that rapidly
dividing tumour cells fail to produce CEA
whereas cells in the stationary phase of
growth are capable of CEA production. It
could be argued, that axillary metastases
which contain large numbers (i.e. > 5%) of
CEA-producing cells are associated with a
favourable prognosis because a significant
proportion of the metastatic cells are
quiescent, the growth fraction is small and
the growth rate ofmetastases is slow. This
could explain the failure of chemotherapy
to increase recurrence-free survival in this
group, since most cytotoxic drugs have
greater toxicity for rapidly proliferating
cells (Madoc-Jones & Bruce, 1967; Golden-
berg et al., 1971; Barranco & Novak, 1974;
Twentyman & Bleehen, 1975). Conversely,
those patients with metastases that con-
tain only a small proportion of CEA
positive cells or none at all might be
expected to have a worse prognosis
because of the more aggressive nature of
the tumour, and would be expected to
show a good response to chemotherapy
because of the larger proportion of divid-
ing cells. Although, this proved true for
patients with metastases that were weakly
positive for CEA, there was no improve-
ment in recurrence-free survival in CEA-
negative cases. One possible interpretation
is that the CEA-negative cases represent
the most aggressive end ofthe spectrum of
tumour growth and that chemotherapy
was not capable ofcontrolling the disease.
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An alternative explanation of the find-
ings is that CEA may induce an immune
response and that this could affect the rate
of progression of disease. However, the
evidence for this is somewhat tenuous
(Carrel et al., 1977; Hammarstrom et al.,
1977; Kapsopoulou-Dominos & Anderer,
1979; Staab et al., 1980b).
Whatever the explanation of these
results, it does appear that the CEA status
of axillary node metastases from patients
with node-positive operable breast cancer
may be of some clinical relevance in
relation to prognosis and selection of
patients for chemotherapy. The immuno-
peroxidase technique used throughout this
study could be performed by any routine
pathology laboratory and is relatively
inexpensive. Clearly, it is important to
repeat these analyses periodically as the
duration of follow-up increases in order to
determine whether the differences des-
cribed above persist, and to detect any
further trends that are not yet apparent
which might be of clinical value.
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